The largest randomized study of fluid intake restrictions showed no benefit from the restrictions, according to its senior ...

CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...

CHICAGO -- Coming this weekend, the American College of Cardiology (ACC) annual conference will feature research exploring ...

Novo Nordisk has submitted a supplemental application to the FDA for Rybelsus 14 mg to lower cardiovascular risk in adults ...

Late-breaking data showed almost all patients achieved normal blood clotting and vessel repair after bentracimab infusion.

Injectable semaglutide has better bioavailability, researchers say, but the many patients who want an oral drug are an unmet ...

Researchers suggest the 20% reduction in nonfatal heart attacks was the primary driver of this benefit for patients with type ...

The “neutral” trial, troubled by the COVID-19 pandemic, found that intensive medical therapy didn’t lower events in INOCA.

DUBLIN and BRIDGEWATER, N.J. - Amarin Corporation plc (NASDAQ:AMRN) announced today that it will present new in vitro data on its cardiovascular drug at the upcoming American College of Cardiology ...

DUBLIN and BRIDGEWATER, N.J. - Amarin Corporation plc (NASDAQ:AMRN) announced today that it will present new in vitro data on its cardiovascular drug at the upcoming American ... poster presentations ...

Three months of dual antiplatelet therapy after PCI may safely balance thrombosis and bleeding risk in both patients with low ...

ACC, the therapist’s employer and his professional ... Mentally you’re doing really well, you’re on the right medication.” Then in January, the woman said she got a text on her sex worker ...